| Description | Parsaclisib (INCB050465) is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP) |
| In vitro | Parsaclisib 在B细胞和T细胞增殖中展现显著活性，其IC50值介于0.2至2 nM。在体外环境下，Parsaclisib 抑制多种DLBCL和MCL细胞系的增殖，EC50值均低于10 nM[1]。 |
| Target activity | PI3Kδ:1 nM (at 1 mM ATP) |
| Synonyms | INCB050465 |
| molecular weight | 432.88 |
| Molecular formula | C20H22ClFN6O2 |
| CAS | 1426698-88-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 122 mg/mL (281.83 mM), Sonication is recommended. |
| References | 1. Niu Shin, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Research. 2015, Aug. 75(15). 2. Shin N, et, al. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy. J Pharmacol Exp Ther. 2020 Jul;374(1):211-222. 3. Yue EW, et, al. INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ). ACS Med Chem Lett. 2019 Oct 17;10(11):1554-1560. |